Primus Pharmaceuticals

“We [Primus Pharmaceuticals] have conducted two clinical trials of our anti-inflammatory product, Limbrel, in Russia under the direction of AmeRuss. The first was a 103 subject, 1 month pilot study performed at 3 investigative sites with limited end point data parameters. The second was a more complicated 3 month, 220 subject trial conducted at 7 sites and involving multiple end point parameters. In both cases, AmeRuss achieved rapid enrollment with extremely low dropout rate (only 3 of 223 randomized in the second trial) and conducted the trial professionally and efficiently, on time and on budget. The very few administrative issues were resolved quickly and easily. Data queries were relatively few and always minor and were resolved expeditiously.

AmeRuss was arguably the most pleasant and professionally satisfying relationship we have had with a CRO and we definitely plan to work with them in future clinical trials.”

Robert M. Levy, MD

Director of Clinical Development

Primus Pharmaceuticals